The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Gene Expression Profile of BRCA ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Open accessAbstract
Purpose: To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC). Methods: A publicly available microarray data set including 61 patients with EOC with either sporadic disease or BRCA½ germline mutations was used for development of the BRCAness profile. Correlation with platinum responsiveness was assessed in platinum-sensitive and platinum-resistant tumor biopsy specimens from six patients with BRCA germline mutations. Association with poly-ADP ribose polymerase (PARP) inhibitor responsiveness and with radiation-induced RAD51 foci formation (a surrogate of homologous recombination) was assessed in Capan-1 cell line clones. The BRCAness profile was validated in 70 patients enriched for sporadic disease to assess its association with outcome. Results: The BRCAness profile accurately predicted platinum responsiveness and mutation status in eight of 10 patient-derived tumor specimens and between PARP-inhibitor sensitivity and resistance in four of four Capan-1 clones. When applied to the 70 patients with sporadic disease, patients with the BRCA-like (BL) profile had improved disease-free survival (34 months v 15 months; log-rank P = .013) and overall survival (72 months v 41 months; log-rank P = .006) compared with patients with a non–BRCA-like (NBL) profile, respectively. The BRCAness profile maintained independent prognostic value in multivariate analysis, which controlled for other known clinical prognostic factors. Conclusion: The BRCAness profile correlates with responsiveness to platinum and PARP inhibitors and identifies a subset of sporadic patients with improved outcome. Additional evaluation of this profile as a predictive tool in patients with sporadic EOC is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Self-citationHallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“Such mechanisms include somatic BRCA1/2 mutations in up to 20% of high-grade ovarian cancers(20) as well as mutations or epigenetic silencing in Fanconi anemia genes, intrinsic HR genes, or other DNA damage-response genes.(5,15,17,19,23)”
BackgroundSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Self-citationResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationGodwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
The Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822 · cited 1×
“Both BRCA1 and BRCA2 proteins are involved in the process of homologous recombination (HR), which mediates repair of double-stranded DNA breaks.(1) Patients with ovarian cancer with germline mutations in either BRCA1 or BRCA2 genes exhibit impaired ability to repair double-stranded DNA breaks via HR, which may partly…”
BackgroundBRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Self-citationLoss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502
Training v-Support Vector Classifiers: Theory and Algorithms
Chang, C.-C., & Lin, C.-J. (2001) · Neural Computation · doi:10.1162/089976601750399335 · Cited by 499
Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Self-citationImproved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Self-citationEMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
Shattuck-Eidens, D. (1997) · JAMA · doi:10.1001/jama.1997.03550150046034 · Cited by 374
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Self-citationA Paradigm for Class Prediction Using Gene Expression Profiles
Radmacher, M. D., McShane, L. M., & Simon, R. (2002) · Journal of Computational Biology · doi:10.1089/106652702760138592 · Cited by 313
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282
Mol, C. D., Hosfield, D. J., & Tainer, J. A. (2000) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(00)00028-8 · Cited by 265
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer
Teodoridis, J. M., Hall, J., Marsh, S., Kannall, H. D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H. L., Strathdee, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1187 · Cited by 256
Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer
Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., Libermann, T. A., & Cannistra, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.070 · Cited by 255
Self-citationInactivation of BRCA1 and BRCA2 in Ovarian Cancer
Hilton, J. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1396 · Cited by 218
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy
Quinn, J. E., James, C. R., Stewart, G. E., Mulligan, J. M., White, P., Chang, G. K. F., Mullan, P. B., Johnston, P. G., Wilson, R. H., & Harkin, D. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1083 · Cited by 208
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
Gallagher, D. J., & Kemeny, N. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4626 · Cited by 174
Classification of microarrays to nearest centroids
Dabney, A. R. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti681 · Cited by 151
Frequency of BRCA1 Dysfunction in Ovarian Cancer
Geisler, J. P. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.1.61 · Cited by 141
Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer
Spentzos, D., Levine, D. A., Kolia, S., Otu, H. H., Boyd, J. A., Libermann, T. A., & Cannistra, S. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9363 · Cited by 136
Self-citationSomatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
Foster, K. A., Harrington, P. A., Kerr, J., Russell, P. A., DiCioccio, R. A., Scott, I., Jacobs, I. J., Chenevix‐Trench, G., Ponder, B. A. J., & Gayther, S. A. (1996) · PubMed · Cited by 119
Gene-expression profiling in epithelial ovarian cancer
Konstantinopoulos, P. A., Spentzos, D., & Cannistra, S. A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1178 · Cited by 115
Self-citationAudeh, M. W., Penson, R. T., Friedlander, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5500 · Cited by 107
Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., & Brown, R. E. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80047-5 · Cited by 100
Mechanisms of drug resistance in ovarian cancer
Johnson, S. W., Ozols, R. F., & Hamilton, T. C. (2010) · Cancer · doi:10.1002/cncr.2820710224 · Cited by 99
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82
Konstantinopoulos, P. A., Fountzilas, E., Pillay, K., Zerbini, L. F., Libermann, T. A., Cannistra, S. A., & Spentzos, D. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-59 · Cited by 61
Self-citationFreitas, S., Moore, D. H., Michael, H., & Kelley, M. R. (2003) · PubMed · Cited by 47
Treating Cancer by Targeting a Weakness
Brody, L. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr052331 · Cited by 43
Optimality Driven Nearest Centroid Classification from Genomic Data
Dabney, A. R., & Storey, J. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001002 · Cited by 35
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Metadata
- Authors
- Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-01
- Volume
- 28
- Issue
- 22
- Pages
- 3555-3561
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156077962
- Cited by
- 483
- References
- 45
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.